CeriBell (CBLL) to Release Earnings on Monday

CeriBell (NASDAQ:CBLL) is expected to be announcing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to post earnings of ($0.45) per share and revenue of $27.2760 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Trading Up 3.1%

CBLL opened at $18.81 on Friday. The company has a market cap of $713.65 million, a P/E ratio of -11.54 and a beta of 0.81. The company’s 50 day moving average is $18.52 and its 200-day moving average is $19.11. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. CeriBell has a 1-year low of $10.85 and a 1-year high of $24.33.

Insider Activity at CeriBell

In other CeriBell news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the completion of the transaction, the insider owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. This represents a 5.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $19.90, for a total value of $776,100.00. Following the completion of the sale, the chief executive officer owned 802,317 shares in the company, valued at approximately $15,966,108.30. This represents a 4.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 300,685 shares of company stock worth $5,935,326 over the last 90 days. 17.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its stake in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CeriBell in the 3rd quarter valued at approximately $33,000. Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after purchasing an additional 854 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of CeriBell in the third quarter worth $135,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Canaccord Genuity Group dropped their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.